About BTB/POZ domain-containing protein KCTD9
BTB/POZ domain-containing protein KCTD9 (KCTD9) is a protein
from Homo sapiens identified by UniProt accession
Q7L273, 389 residues long.
MolForge cross-references it against 0 known binders and
146 disease associations.
Target properties
| Protein name | BTB/POZ domain-containing protein KCTD9 |
| UniProt accession | Q7L273 |
| Gene | KCTD9 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (146)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.31
- body height · score 0.31
- reticulocyte count · score 0.30
- Immature Reticulocyte Fraction Measurement · score 0.27
- heel bone mineral density · score 0.26
- Red cell distribution width · score 0.26
- BMI-adjusted waist-hip ratio · score 0.24
- BMI-adjusted waist circumference · score 0.22
- triglyceride measurement · score 0.22
- waist-hip ratio · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7L273-F1 | alphafold | PREDICTED | 89.77 | — |
Amino-acid sequence (389 residues)
MRRVTLFLNG SPKNGKVVAV YGTLSDLLSV ASSKLGIKAT SVYNGKGGLI DDIALIRDDD VLFVCEGEPF IDPQTDSKPP EGLLGFHTDW LTLNVGGRYF TTTRSTLVNK EPDSMLAHMF KDKGVWGNKQ DHRGAFLIDR SPEYFEPILN YLRHGQLIVN DGINLLGVLE EARFFGIDSL IEHLEVAIKN SQPPEDHSPI SRKEFVRFLL ATPTKSELRC QGLNFSGADL SRLDLRYINF KMANLSRCNL AHANLCCANL ERADLSGSVL DCANLQGVKM LCSNAEGASL KLCNFEDPSG LKANLEGANL KGVDMEGSQM TGINLRVATL KNAKLKNCNL RGATLAGTDL ENCDLSGCDL QEANLRGSNV KGAIFEEMLT PLHMSQSVR
Explore BTB/POZ domain-containing protein KCTD9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets